Covalent PROTACs: the best of both worlds?

Neil P Grimster1

  • 1Oncology R&D, AstraZeneca Waltham USA neil.grimster@astrazeneca.com.

RSC Medicinal Chemistry
|October 21, 2021
PubMed

Insights

Covalent proteolysis targeting chimeras (PROTACs) merge targeted covalent inhibitors (TCIs) with PROTACs. This emerging field shows promise for expanding the druggable proteome, offering new therapeutic strategies.

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Drug Discovery

Background:

  • Covalent PROTACs integrate targeted covalent inhibitors (TCIs) and proteolysis targeting chimeras (PROTACs).
  • This novel approach aims to leverage the strengths of both TCIs and PROTACs for enhanced therapeutic outcomes.

Discussion:

  • Exploration of early findings in covalent PROTAC research.
  • Analysis of the potential advantages, such as prolonged target engagement and unique degradation profiles.
  • Consideration of the disadvantages, including potential off-target toxicities and challenges in drug design.

Key Insights:

  • Covalent PROTACs represent a nascent but promising area in drug discovery.
  • The combination offers potential for overcoming resistance mechanisms and targeting challenging proteins.
  • Early data suggests significant potential for expanding the druggable proteome.

Outlook:

  • Future development of covalent PROTACs could lead to novel therapeutics.
  • Further research is needed to fully understand and mitigate potential risks.
  • This approach may redefine strategies for protein degradation-based therapies.

Related Concept Videos

Protein Complexes with Interchangeable Parts01:57

Protein Complexes with Interchangeable Parts

Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
2.6K
Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
14.0K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.2K
Tagging and Fusion Proteins01:24

Tagging and Fusion Proteins

Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
7.3K